A retrospective, non-interventional, multicenter, observational chart review study to explore the clinical benefits of retreatment with TKI in the real world. - SEQUENCE

Study identifier:NIS-OTW-XXX-2013/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Retrospective, Non-interventional Study to Evaluate EGFR-Tyrosine Kinase Inhibitor Retreatment in Patients with Locally Advanced or Metastatic EGFR Mutated NSCLC who Previously Treated with EGFR-TKI as First-line Therapy and Chemotherapy as Second-line Therapy – SEQUENCE study

Medical condition

Locally Advanced or Metastatic EGFR Mutated NSCLC.

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

20 Years - 150 Years

Date

Study Start Date: 01 Dec 2013
Estimated Primary Completion Date: 01 Dec 2014
Estimated Study Completion Date: 01 Dec 2014

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Oct 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria